Strybol Pharma Groep
0841.947.033 · rovalta.com · 24/09/2026
ACTIVE
Strybol Pharma Groep
Financial year 2024 · Closed on 31/12/2024
Net result65,6 k €-59,1 %over 1 year
Gross margin68,7 k €-57,1 %over 1 year
Equity109,3 k €+0,1 %over 1 year
Workforce0,0 ETP
Overview
Identity
Source · BCE/KBOStrybol Pharma Groep is a Private limited company incorporated in 2011. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Brugge.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0841.947.033
- Incorporation
- 16/12/2011
- Legal form
- Private limited company
- Registered office
- Maalse Steenweg 319
8310 Brugge · FlandreSee on map - Contributed capital
- 18 600,00 €
- Latest accounts
- 31/12/2024
- Average workforce
- 0,0 ETP
Activities (NACE)
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA
Financials
Source · NBB, 13 filingsTrend over 11 financial years
| 2024 | 2023 | 2022 | 2021 | 2018 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 68,7 k € | -57.1% | 159,9 k € | +125% | 71,2 k € | +0.1% | 71,1 k € | +1.5% | 70,1 k € |
| EBITDA | 64,3 k € | -59.7% | 159,4 k € | +125% | 70,7 k € | +0.8% | 70,2 k € | +0.9% | 69,5 k € |
| Operating result | 64,3 k € | -59.7% | 159,4 k € | +125% | 70,7 k € | +596% | 10,2 k € | +6.5% | 9,5 k € |
| Net result | 65,6 k € | -59.1% | 160,3 k € | +169% | 59,5 k € | +857% | 6,2 k € | +159% | 2,4 k € |
| Balance sheet | |||||||||
| Equity | 109,3 k € | +0.1% | 109,3 k € | +477% | 18,9 k € | +234% | -14,1 k € | -144% | -5,8 k € |
| Total assets | 175 k € | -2.5% | 179,5 k € | +269% | 48,6 k € | +102% | 24,1 k € | -89.6% | 231,2 k € |
| Cash | 27,4 k € | +343% | 6,2 k € | +26.1% | 4,9 k € | +27.1% | 3,9 k € | +188% | 1,3 k € |
| Debts | 65,5 k € | -6.7% | 70,2 k € | +137% | 29,7 k € | -8.5% | 32,5 k € | -86.3% | 236,3 k € |
| Other | |||||||||
| Workforce | 0,0 ETP | 0,0 ETP | – | – | – | ||||
Valuation
Indicative valuation
As an indication, this company is worth
between 500 k€ and 1 M€
See the valuationBoard of directors
Source · NBB, accounts to 31/12/20243 active · 8 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 23/07/2025 | 29/08/2024 | 03/07/2023 | 28/06/2022 | 30/06/2021 | 29/07/2020 |
| General meeting | 20/06/2025 | 31/05/2024 | 31/05/2023 | 31/05/2022 | 31/05/2021 | 31/05/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 13 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 20/06/2025 | 23/07/2025 | Dutch | |
| Abridged model | 31/12/2023 | 31/05/2024 | 29/08/2024 | Dutch | |
| Abridged model | 31/12/2022 | 31/05/2023 | 03/07/2023 | Dutch | |
| Abridged model | 31/12/2021 | 31/05/2022 | 28/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 31/05/2021 | 30/06/2021 | Dutch | |
| Abridged model | 31/12/2019 | 31/05/2020 | 29/07/2020 | Dutch | |
| Abridged model | 31/12/2018 | 31/05/2019 | 01/07/2019 | Dutch | |
| Abridged model | 31/12/2017 | 31/05/2018 | 02/07/2018 | Dutch | |
| Abridged model | 31/12/2016 | 31/05/2017 | 25/07/2017 | Dutch | |
| Abridged model | 31/12/2015 | 14/06/2016 | 15/07/2016 | Dutch | |
| Abridged model | 31/12/2014 | 08/06/2015 | 30/07/2015 | Dutch | |
| Abridged model | 31/12/2013 | 31/05/2014 | 08/07/2014 | Dutch | |
| Abridged model | 31/12/2012 | 30/06/2013 | 10/10/2013 | Dutch |
Valuation
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 500 k€ and 1 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20243 active · 8 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates14/01/2025STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - BENAMING - DIVERSEN - DOEL - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
- Mandates04/03/2016ONTSLAGEN - BENOEMINGEN
- Mandates10/12/2013ONTSLAGEN - BENOEMINGEN
- Other31/01/2012DIVERSEN
- Other29/12/2011RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202465,6 k €↓
- 2024Name changeSTRYBOL PHARMA GROEP
- 2023Annual accounts 2023160,3 k €↑
- 2022Annual accounts 202259,5 k €↑
- 2021Annual accounts 20216,2 k €↑
- 2018Annual accounts 20182,4 k €↑
- 2017Annual accounts 20171,7 k €↑
- 2016Annual accounts 201688,2 €↑
- 2015Annual accounts 2015-3,1 k €↑
- 2014Annual accounts 2014-6,6 k €↑
- 2013Annual accounts 2013-9,1 k €↑
- 2012Annual accounts 2012-9,8 k €
- 2012Name changeDE VELTEM INVEST
- 16/12/2011IncorporationPrivate limited company